Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the
treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant …

The available treatments for relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) have experienced a dramatic change since 2017. Incremental advances in basic …

Greater tumor burden before CD19-targeted chimeric antigen receptor T cell (CAR-T)
therapy predicts lower complete response rate and shorter overall survival (OS) in patients …

CD19 is nearly ubiquitously expressed on B-lymphocytes and in B-cell malignancies.
Although CD19-directed CAR T cells have greatly improved outcomes in B-cell …

Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of
patients with relapsed/refractory large B cell lymphoma (LBCL). However, approximately …

In this issue of Blood, Di Blasi et al highlight the transformational nature of chimeric antigen
receptor (CAR) T cells, as well as the new unmet medical need in diffuse large B-cell …

Chimeric antigen receptor T-cell therapy (CAR-T) is a major advance in managing
aggressive relapsed or refractory B-cell lymphomas; however, relapses are frequent and …

Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin
lymphoma. Relapsed/refractory disease represents remains an unmet medical need …

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment approach
for patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). However, the long …